InvestorsHub Logo
Followers 6
Posts 1400
Boards Moderated 0
Alias Born 08/24/2014

Re: Titan V post# 35732

Wednesday, 08/31/2016 7:50:09 PM

Wednesday, August 31, 2016 7:50:09 PM

Post# of 48316
Any setbacks with CAR-T programs will be positive for Oncosec. Juno had 3 deaths with their CAR-T trial last month. That might be specific to just their company and not other CAR-T companies like Kite....but as quoted by STATNEWS.com last month:

"The fear is that the FDA will take a dim view of the whole CAR-T class, slowing down the progress of each program and forcing companies to delay their expected filings, as Juno already has."

If Oncosec can prove their hypothesis of turning non-responders into responders and make it to market with a viable solution to treating cancer with no adverse side affects ahead of other companies we will be in great shape.

What Punit needs to do is seize the opportunity when it arises. If we get the results we are expecting by years end, he really needs to get the word out on Oncosec and PR the crap out of this. We need articles printed in Forbes, Newsweek, Time magazine. Publicity! Inovio has gotten PR and airtime on tv (MADMONEY). We need some of that to get people interested here.